Importance of Circumferential Resection Margin in Management of Esophageal Cancer

Binay Thakur¹, Mukti Devkota¹, Li Aiming¹, Ashis Pun², Manish Chaudhary¹
¹Department of Surgical Oncology. BP Koirala Memorial Cancer Hospital, Bharatpur, Nepal.
²Department of Surgery, Bharatpur Hospital

ABSTRACT
Esophagectomy (R0) remains the gold standard for the management of esophageal cancer. But due to close vicinity of esophagus with the major structures like heart, aorta, vertebral column, tracheobronchial tree and lungs, a wider circumferential resection is generally not possible and a R1/ R2 resection might occur. Therefore, locoregional recurrence rates of esophageal cancer are reported to be as high as 52%. The Royal College of Pathologists (RCP) and The College of American Pathologists (CAP) define circumferential resection margin (CRM) differently. A mean overall CRM involvement was found to be 40.7% (RCP criteria) and 11.8% (CAP criteria). Two meta-analyses have shown poor survival in CRM positive cases. CRM positivity in T1/ T2 lesions should not occur unless there is a surgical fault. For T3 lesions, a higher rate of CRM positivity has been documented. Therefore, a wider CRM using transthoracic approach appears mandatory, especially for T3 lesions.

Keywords: Esophageal cancer; Esophagectomy; Resection margin.

Introduction
Esophageal cancer is one of aggressive cancers with an increasing incidence worldwide.¹,² There has been persistently improvement in diagnostic and therapeutic modalities which have reduced the morbidity and post-operative mortality.³

Usual treatment protocols include preoperative chemoradiation for squamous cell carcinoma and perioperative chemotherapy for adenocarcinoma. Hence, Surgery remains the gold standard treatment at present.⁴,⁵

Like any other gastrointestinal malignancies, achieving R0 resection remains the main goal of surgery. But due to close vicinity of esophagus with the major structures like heart, aorta, vertebral column, tracheobronchial tree and lungs, a wider circumferential resection is generally not possible and a R1/ R2 resection might occur. Therefore, locoregional recurrence rates of esophageal cancer are reported to be as high as 52%.⁶,⁷ Histologic characteristics like depth of tumor invasion, lymph node involvement, and proximal and distal resection margins are accepted risk factors for patients’ survival and tumor recurrence⁸⁻¹⁰, while the role of circumferential resection margin (CRM) is still debatable in the literature.

There is no unanimous definition of CRM in esophageal cancer. The Royal College of Pathologists (RCP) defines a positive CRM as a tumor at or within 1 mm of the resection margin¹¹ while The College of American Pathologists (CAP) only regards the occurrence of tumor at the resection margins as CRM positive.¹² In metanalysis, Chan et al showed Rates of CRM involvement were 15.3 per cent (173 of 1133) and 36.5 per cent (889 of 2433) according to the CAP and RCP criteria respectively.¹³ The median CRM positive rates 40.0% (range, 20.3% to 67.4%) and 17.2% (range, 5% to 25.5%) according to the RCP and CAP criteria, respectively were reported in another metanalysis by Wu et.al.¹⁴ Few studies

Correspondence
Dr Binay Thakur, Department of Surgical Oncology, BP Koirala Memorial Cancer Hospital, Bharatpur, Nepal.
Email: binaythakur@hotmail.com, Phone: +977-9855055931
have directly compared the prognostic significance of the different classification systems with conflicting results. These data suggest, there is an urgent need to reframe the technique of esophagectomy where the boundaries of excision would follow embryological or fascial plane rather than simply adventitial plane. Motivated by results of total mesorectal excision for rectal cancer from the point of view of reducing CRM rates and locoregional recurrences, there has been a growing evidence suggesting existence of “Mesoesophagus”.

The procedure has been named as Total Mesoesophageal excision (TME). TME for esophageal cancer appears to decrease the incidence of locoregional recurrence by reducing the rates of CRM positivity.

Here, we review the importance of CRM and effect of CRM positivity on locoregional recurrence and overall survival.

**Impact on Survival**

Majority of studies confirmed a prognostic impact of CRM on survival. Two available meta-analysis found a significant association between a positive CRM and patients' survival irrespective of RCP or CAP criteria. In the metaanalysis by Chan et al., an increased OR of 4.02 (95% CI 2.25–7.20; p < 0.001) when applying RCP criteria and an increased OR of 2.52 (95% CI 1.96–3.25; p < 0.001) when using CAP criteria in 5-year mortality rates of patients with a CRM involvement was found. The CAP criteria resulted in larger ORs than the RCP criteria. In addition, Wu et al. in another metaanalysis of 19 studies (2 prospective and 17 retrospective) found the pooled hazard ratio (HR) for survival to be 1.510 (95% CI 1.329–1.717; p < 0.001) and 2.053 (95% CI, 1.597–2.638; p < 0.001) according to the RCP and CAP criteria, respectively. Positive circumferential resection margin was associated with worse survival in patients with T3 stage disease according to the RCP (HR, 1.381; 95% CI, 1.028–1.584; p <0.001) and CAP (HR, 2.457; 95% CI, 1.902–3.175; p < 0.001) criteria, respectively. Positive circumferential resection margin was associated with worse survival in patients receiving neoadjuvant therapy according to the RCP (HR, 1.676; 95% CI, 1.023–2.744; p = 0.04) and CAP (HR, 1.847; 95% CI, 1.226–2.78; p = 0.003) criteria, respectively. Both the metanalyses showed poor survival of CRM positive patients.

Other recent retrospective studies also supported these results. A multicenter study comprising a total of 2,815 patients after esophagectomies found a reduced overall survival for patients with a positive CRM as compared to patients with tumor-free margins (17.1 vs. 28.0 months; p < 0.001) irrespective of the nodal status. However, some studies were not able to show an effect of the CRM status on overall survival. Khan et al. investigated 329 patients treated for esophageal squamous cell carcinoma (SCC) by esophagectomy. No statistically significant association between the CRM status and survival was observed (p = 0.57). In a study by O’Farrell et al., a positive CRM according to RCP or CAP criteria did not show any influence on survival in multivariate analysis. In a recent study by Gbadan et al., a total of 180 patients following esophagectomy were compared. Neither RCP (HR 1.081; 95% CI 0.769–1.518; p = 0.655) nor CAP (HR 1.214; 95% CI 0.830–1.777; p = 0.317) criteria yielded an association to overall survival.

While analyzing specifically pT3N0M0 in SCC in 112 patients without neoadjuvant treatment, CRM+ was found in 77.7% with median overall survival (OS) of 29.1 months according to RCP; whereas CRM+ was found in 21.4% with median OS of 24.3 months according to CAP (p = ns). Reclassifying CRM with a cutoff value of 600 microns showed better OS with CRM > 600 microns than CRM < 600 microns (p=.003).

**Impact on Locoregional Recurrence**

Loco-regional recurrences seem to be the predominant failure pattern in CRM positive patients. In the first study of CRM involvement by Sagar et al., significantly (p < 0.01) more patients with a positive CRM (55%) developed a local recurrence as compared to those without involvement of the CRM (13%). These results were later proven by other studies, which also identified a prognostic role of a positive CRM on recurrences. Chao et al. found a significant influence of an involved CRM not only on locoregional but also on distant recurrences, while an involvement to the CRM of less than 1 mm was associated with early locoregional recurrences. In another study, involvement of the CRM was only associated to recurrences, being outside the lymphatic drainage of the esophagus and the gastroesophageal junction. Interestingly, Verhage et al. were able to demonstrate a prognostic effect only when using CAP criteria in multivariate analysis (HR 2.086; 95% CI 1.320–3.296; p = 0.002). CRM involvement was
the strongest predictor of recurrence in their analysis comprising only pT3 adenocarcinomas.\textsuperscript{16} The results of the latter study were supported by Hulshoff et al. who identified margin involvement according to CAP criteria to be associated with local recurrence in surgically treated patients (p = 0.004) as well as in patients who also received neoadjuvant therapy prior to surgery (p = 0.001).\textsuperscript{17} However, when applying RCP criteria, no significant associations were observed.\textsuperscript{17} In a study of 160 ESCC, the usage of RCP criteria also did not show any relationship to local recurrence (p = 0.64) while judging by CAP criteria did (p = 0.02).\textsuperscript{25} In contrast to the latter studies, the paper of Harvin et al. investigated only pT3 adenocarcinomas and authors failed to detect an effect of a positive CRM on recurrences after performing a propensity score matching by histopathological and clinical parameters.\textsuperscript{34}

**Impact of Neoadjuvant Treatment**
Perioperative chemotherapy and preoperative chemoradiotherapy has become the standard of treatment for esophageal cancer.\textsuperscript{4,5} However, the influence of neoadjuvant therapy on the CRM remains unclear. Chao et al. reported a decline in CRM involvement when comparing patients treated with surgery alone (CAP 22.2%, RCP 40.1%), preoperative chemotherapy (CAP 15.8%, RCP 34.3%), and preoperative chemoradiation (CAP 11.2%, RCP 31.9%).\textsuperscript{33} In a subset of 123 patients, Thompson et al. found significantly less CRM involvement in patients treated with neoadjuvant chemoradiotherapy as compared to patients who were treated by surgery alone (22 vs. 50%; p < 0.001).\textsuperscript{35} However, no association between CRM status and survival was observed in these patients (p = 0.184).\textsuperscript{35} The influence of neoadjuvant therapy on CRM status was supported by Reid et al.,\textsuperscript{36} who found a reduction of CRM involvement in patients treated with neoadjuvant chemoradiotherapy in multivariate analysis (OR 0.116; 95% CI 0.035–0.382; p < 0.0001). In contrast, Sujendran et al.\textsuperscript{37} observed a reduction of CRM positivity in patients treated with neoadjuvant chemotherapy alone as compared to those who did not receive any treatment prior to surgery (31 vs. 55%; p = 0.005). In another study, the CRM had no significant influence on disease-free survival after neoadjuvant treatment, irrespective of CAP or RCP criteria. Thus, the authors proposed an additional CRM cutoff of 0.3 mm for patients treated with neoadjuvant therapy.\textsuperscript{17} Okada et al. demonstrated that the usage of CAP criteria as opposed to RCP criteria in regards to CRM status was of greater prognostic significance after neoadjuvant therapy in multivariate analysis.\textsuperscript{25} Another retrospective study in 177 patients specifically looked at perioperative chemotherapy and surgery and CRM. The majority (94.9%) received ECX (epirubicin, cisplatin, capecitabine), and all had clear proximal/distal resection margins. CRM was defined as positive when it was directly infiltrated (infiltrated CRM) or when tumor cells were detected within 1 mm from CRM (close CRM) and as negative (CRM-) when tumor cells were found in a distance > 1 mm from CRM. Positive CRM was found in 46.9%. Of them, infiltrated CRM was recorded in 20.3% and close CRM in 26.6%. Adjuvant chemotherapy was administered to 74.6% patients. Lympho-vascular invasion and primary site in the lower esophagus were independently associated with higher risk of CRM positivity. Patients with infiltrated CRM, compared to those with close CRM and those CRM- had the shortest median time-to-relapse (11.4 vs. 15.6 vs. 22.1 months, respectively, p = 0.005) and overall survival (18.7 vs. 23.1 vs. 38.8 months, respectively, p = 0.001). However, CRM status was not an independent predictor of poor outcome. Symptomatic isolated locoregional recurrences were rare in both CRM positive and CRM-patients (7.1% vs. 9.6%, p 0.736), as well as in infiltrated vs. non-infiltrated CRM (CRM- and close CRM) (0% vs. 11.0%), (p = 0.110). Authors concluded, although CRM status is associated with poor outcome, it does not represent an independent prognostic factor.\textsuperscript{38}

A recent review on pT3 SCC of esophagus (n = 217) divided the patients in upfront surgery (n = 138) vs chemoradiation followed by surgery. CRM status was assessed and divided into CRM > 1 mm, 0 < CRM < 1 mm, and tumor at CRM. In the upfront surgery group, patients with 0 < CRM < 1 mm showed equivalent overall survival to those with CRM > 1 mm (log-rank p = 0.817) and significantly outlived those with tumor at CRM (log-rank p < 0.001). However, in the chemoradiation + surgery group, CRM > 1 mm failed to show survival superiority to CRM between 0 and 1 mm or involved by cancer (log-rank p = 0.390). Authors concluded, a negative CRM, even though being <1 mm, is adequate for pT3 Esophageal SCC patients undergoing upfront esophagectomy. However, the CRM status is less prognostic in pT3 patients undergoing chemoradiation followed by esophagectomy.\textsuperscript{39}
Impact of Adjuvant Treatment
A majority of the patients treated for esophageal cancer receive adjuvant therapy. The prognostic influence of the CRM still remains unclear and only very few studies have addressed this issue. Markar et al. demonstrated a significant benefit for CRM positive patients treated with adjuvant therapy comprising either radiotherapy or radiochemotherapy (p = 0.015). The results indicated improved overall survival (p = 0.087) and reduced distant recurrences (p = 0.058). However, no effect (p = 0.851) on loco-regional recurrences was found.

Park et al. investigated the effect of postoperative radiotherapy in esophageal squamous cell carcinomas only. They were not able to demonstrate a significant survival benefit between patients with positive or negative CRM (p = 0.883) treated with adjuvant radiotherapy. Only patients with a positive CRM and pN2-3 stage yielded a benefit from this treatment in regards to loco-regional recurrences. However, the latter finding failed to reached statistical significance (p = 0.057).

Impact of Type of Surgery
Association of type of surgery and CRM has been also a controversial issue. Esophagectomies can be done using either transhiatal or a transthoracic technique. The influence of the surgical approach on CRM involvement is still debatable. Suttie et al. found an increased number of positive CRM involvement in patients treated with a transhiatal approach as compared to a transthoracic approach. Another study also found an increased CRM involvement in patients treated with a transhiatal approach as compared to patients treated with a transthoracic approach using CAP criteria (p = 0.026). However, when applying RCP criteria, the difference did not remain significant (p = 0.086). Scheepers et al. further divided transhiatal esophageal resections into a laproscopic and an open group. However, they were not able to detect any significant differences in regards to CRM involvement (p = 0.192). Similarly, Pultrum et al. could not find an association between type of surgery and CRM (p = 0.693).

Conclusion and Future Direction
Hence, it is obvious from the literature that a wide range of CRM involvement (8.6–83.1%) has been reported. This is due to various pathologic classification systems -RCP and CAP criteria. The criteria of positive CRM in esophageal cancer by the RCP are partially derived from rectal cancer. However, a comparison between esophageal and rectal cancer in regards to resection criteria is questionable since anatomic boundaries are different. Even though both entites are localized in an extraperitoneal position and miss a serosal cover, only the rectum is surrounded by the mesorectum. Bulky T3 tumors of the rectum can be resected anatomically with negative margins, while the same principles do not apply for bulky T3 tumors of the esophagus. This is caused by the proximity of the esophagus to central organs that cannot be resected like aorta, atrium, trachea, spine and lung. So close margins have to be anticipated in a high number of such tumors leading to larger amount of CRM positive tumors in regards to CAP as opposed to RCP criteria in terms of prognostic significance, risk stratification.

Nevertheless, R1 status in early tumors (T1-2) is considered to be caused by inadequate surgery. Results of such studies investigating the CRM status including early tumor stages have to be interpreted with caution.

Whatsoever, evaluation of the CRM remains an extremely important prognostic factor in esophageal cancer. A deep understanding of various surgical procedures would definitely show a transthoracic approach to be a better approach to achieve wider CRM, especially for T3 tumors. Though concept of TME sounds very scientific, evidences are still lacking. Logically, dissection in an mesoesophageal and embryological plane would definitely help in achieving an extra layer of dissection beyond the esophageal adventitia and this, in return, would reduce the locoregional recurrence.

References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–E386.
2. Njei B, McCarty TR, Birk JW. Trends in 12 esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis. J Gastroenterol Hepatol 2016;31: 1141–1146.
3. Markar S, Gronnier C, Duhamel A, Bigourdan JM, Badic B, du Rieu MC, et al. Pattern of postoperative mortality after esophageal cancer resection according to center volume: results from a large European multicenter study. Ann Surg Oncol 2015;22:2615–2623.

4. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med.2012 May 31;366(22):2074-84.

5. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capcitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019 May 11;393(10184):1948-1957.

6. Law SY, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg 1996;83:107–111.

7. Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg 2000;87:1426–1433.

8. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, et al. Adenocarcinoma of the gastrooesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg 2007;246:1–8.

9. Mariette C, Taillier G, Van Seuningen I, Triboulet JP: Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg 2004;78:1177–1183.

10. Wang YC, Deng HY, Wang WP, He D, Ni PZ, Hu WP, et al. Positive esophageal proximal resection margin: an important prognostic factor for esophageal cancer that warrants adjuvant therapy. J Thorac Dis 2016;8:2512–2518.

11. Mapstone NP: Dataset for the Histopathological Reporting of Oesophageal Carcinoma, ed 2.

12. Washington K, Berlin J, Branton P, Lawrence B. Protocol for the Examination of Specimens from Patients with Carcinoma of the Esophagus. Dig Surg 2018;35:196–203.

13. Chan DS, Reid TD, Howell I, Lewis WG. Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer. Br J Surg 2013;100:456–464.

14. Wu J, Chen QX, Teng LS, Krasna MJ. Prognostic significance of positive circumferential resection margin in esophageal cancer: a systematic review and meta-analysis. Ann Thorac Surg 2014;97:446–453.

15. Deeter M, Dorer R, Kuppusamy MK, Koehler RP, Low DE. Assessment of criteria and clinical significance of circumferential resection margins in esophageal cancer. Arch Surg Chic Ill 1960;144:618–624.

16. Verhage RJ, Zandvoort HJ, ten Kate FJ, van Hillegersberg R. How to define a positive circumferential resection margin in T3 adenocarcinoma of the esophagus. Am J Surg Pathol 2011;35:919–926.

17. Hulshoff JB, Faiz Z, Karrenbeld A, Kats-Ugurlu G, Burgerhof JG, Smit JK, et al. Prognostic value of the circumferential resection margin in esophageal cancer patients after neoadjuvant chemoradiotherapy. Ann Surg Oncol 2015;22(suppl 3):S1301–S1309.

18. O’Farrell NJ, Donohoe CL, Muldoon C, Costelloe JM, King S, Ravi N, et al. Lack of independent significance of a close (<1 mm) circumferential resection margin involvement in esophageal and junctional cancer. Ann Surg Oncol 2013;20:2727–2733.

19. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986 Jun 28;1(8496):1479-82.

20. Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012;379(9829):1887-1892.

21. Cuesta MA, Weijs TJ, Bley RL, van Hillegersberg R, van Berge Henegouwen MI, Gisbertz SS, et al. A new concept of the anatomy of the thoracic oesophagus: the meso-oesophagus. Observational study during thoracoscopic esophagectomy. Surg Endosc 2015 Sep;29(9):2576-82.

22. Li Z, Fu J, Du Z. Total mesoesophageal excision by thoracoscopy and laparoscopy in the radical resection of esophageal carcinoma. J Thorac Dis 2019 Jul;11(7):3180-3182.
23. Akiyama Y, Iwaya T, Endo F, Nikai H, Sato K, Baba S, et al. Thoracoscopic esophagectomy with total meso-esophageal excision reduces regional lymph node recurrence. Langenbecks Arch Surg 2018 Dec;403(8):967-975.

24. Gilbert S, Martel AB, Seely AJ, Mazlak DE, Shamji FM, Sundaresan SR, et al. Prognostic significance of a positive marginal resection margin after esophageal cancer resection. J Thorac Cardiovasc Surg 2015;149:548–555; discussion 555.

25. Okada N, Fujii S, Fujita T, Kanamori J, Kojima T, Hayashi R, et al. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or with-out neoadjuvant chemotherapy. Surgery 2016;159:441–450.

26. Khan OA, Fitzgerald JJ, Soomro I, Beggs FD, Morgan WE, Duffy JP. Prognostic significance of circumferential resection margin involvement following oesophagectomy for cancer. Br J Cancer 2003;88:1549–1552.

27. Mirnezami R, Rohatgi A, Sutcliffe RP, Hamouda A, Chandrakumaran K, Botha A, et al. Multivariate analysis of clinicopathological factors influencing survival following esophagectomy for cancer. Int J Surg Lond Engl 2010;8:58–63.

28. Park HJ, Kim HJ, Chie EK, Kang CH, Kim YT. The influence of circumferential resection margin status on loco-regional recurrence in esophageal squamous cell carcinoma. J Surg Oncol 2013;107:762–766.

29. Ghadban T, Reeh M, Koenig AM, Nentwich MF, Bellon E, Izbicki JR, et al. Prognostic significance or not? The positive circumferential resection margin in esophageal cancer: impact on local recurrence and overall survival in patients without neoadjuvant treatment. Ann Surg 2016, Epub ahead of print.

30. Yang YS, Wang YC, Deng HY, Yuan Y, Wang ZQ, He D, et al. Prognostic value of circumferential resection margin in T3N0M0 esophageal squamous cell carcinoma. Ann Transl Med 2018 Aug;6(15):303.

31. Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003;97:1616–1623.

32. Sagar PM, Johnston D, McMahon MJ, Dixon MF, Quirke P. Significance of circumferential resection margin involvement after oesophagectomy for cancer. Br J Surg 1993;80:1386–1388.

33. Chao YK, Yeh CJ, Chang HK, Tseng CK, Chu YY, Hsieh MJ, et al. Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 2011;18:529–534.

34. Harvin JA, Lahat G, Correa AM, Lee J, Maru D, Ajani J, et al. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg 2012;143:412–420

35. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–2084.

36. Reid TD, Chan DS, Roberts SA, Crosby TD, Williams GT, Lewis WG. Prognostic significance of circumferential resection margin involvement following oesophagectomy for cancer and the predictive role of endoluminal ultrasonography. Br J Cancer 2012;107:1925–1931.

37. Sujendran V, Wheeler J, Baron R, Warren BF, Maynard N. Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer. Br J Surg 2008;95:191–194.

38. Patrão AS, Papaxoinis G, Kordatou Z, Weaver JM, Owen-Holt V, Alkhaffaf B, et al. Prognostic significance of positive circumferential resection margin post neoadjuvant chemotherapy in patients with esophageal or gastro-esophageal junction adenocarcinoma. Eur J Surg Oncol 2019 Mar;45(3):439-445.

39. Liu CY, Hsu PK, Hsu HS, Wu YC, Chuang CY, Lin CH, et al. Prognostic impact of circumferential resection margin in esophageal cancer with or without neoadjuvant chemoradiotherapy. Dis Esophagus 2020 Feb 17 [Epub ahead of print] PubMed PMID: 32065226.

40. Suttie SA, Nanthakumaran S, Mofidi R, Rapson T, Gilbert FJ, Thompson AM, et al. The impact of operative approach for oesophageal cancer on outcome: the transhiatal approach may influence circumferential margin involvement. Eur J Surg Oncol 2012;38:157–165.
41. Scheepers JJ, van der Peet DL, Veenhof AA, Cuesta MA. Influence of circumferential resection margin on prognosis in distal esophageal and gastroesophageal cancer approached through the transhiatal route. Dis Esophagus 2009;22:42–48.

42. Pultrum BB, Honing J, Smit JK, van Dullemen HM, van Dam GM, Groen H, et al. A critical appraisal of circumferential resection margins in esophageal carcinoma. Ann Surg Oncol 2010;17:812–820.

43. Bernstein TE, Endreseth BH, Romundstad P, Wibe A. Norwegian Colorectal Cancer Group: Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg 2009;96:1348–1357.

44. Wibe A, Rendedal PR, Svensson E, Norstein J, Eide TJ, Myrvold HE, et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002;89:327–334.

45. Khan OA, Cruttenden-Wood D, Toh SK. Is an involved circumferential resection margin following oesophagectomy for cancer an important prognostic indicator? Interact Cardiovasc Thorac Surg 2010;11:645–648.

46. Griffiths EA, Brummell Z, Gorthi G, Pritchard SA, Welch IM. The prognostic value of circumferential resection margin involvement in oesophageal malignancy. Eur J Surg Oncol 2006;32:413–419.

47. Karstens KE, Izbicki JR, Reeh M. Does the Margin Matter in Esophageal Cancer. Dig Surg 2018;35(3):196-203.